Completion rate of primary posterior continuous curvilinear capsulorhexis and vitreous disturbance during congenital cataract surgery.
OBJECTIVE
We sought to document the completion rate of primary posterior continuous curvilinear capsulorhexis during congenital cataract surgery and determine the incidence of disruption of vitreous face during this procedure.


METHODS
One hundred six consecutive eyes of patients undergoing posterior continuous curvilinear capsulorhexis (PCCC) during congenital cataract surgery were evaluated prospectively for completion of PCCC and disruption of vitreous face. PCCC was performed under high-viscosity sodium hyaluronate (Healon GV 1.4%) initiated with 26 g of cystotome and later completed with Kraff-Uttrata forceps by frequent grasping and regrasping of the flap. Completion of PCCC and disruption of vitreous face during the procedure was noted. Even in cases of disrupted vitreous face, PCCC was performed and completed with forceps and, later, disruption of vitreous face was managed with 2-port automated limbal anterior vitrectomy. The size of PCCC was measured. An Alcon AcrySof SA30AL was implanted in-the-bag if the PCCC was 4 mm or smaller and in the sulcus when the PCCC was larger than 4 mm.


RESULTS
The mean age of the 106 pediatric patients was 17 +/- 26 months (median, 6 months; range, 1 month to 8 years). PCCC was completed in all the eyes. Disruption of vitreous face during PCCC was noted in 5 of 106 (4.7%) eyes. The mean size of PCCC was 3.6 +/- 0.7 mm. A total of 98 (92.5%) had in-the-bag, and 8 (7.5%) eyes had sulcus implantation of IOL.


CONCLUSIONS
PCCC was completed in all eyes with minimal disruption of vitreous face in a well-controlled manner under high-viscosity viscoelastics.
Dholakia
Sheena A
SA
Iladevi Cataract and IOL Research Centre, Gurukul Road, Memnagar, Ahmedabad 380052, India.
Praveen
M R
MR
Vasavada
Abhay R
AR
Nihalani
Bharti
B
D019923:Capsulorhexis / Q000009:adverse effects* / Q000706:statistics & numerical data*; D002386:Cataract / Q000151:congenital*; D002648:Child; D002675:Child, Preschool; D005128:Eye Diseases / Q000209:etiology*; D006801:Humans; D006820:Hyaluronic Acid / Q000627:therapeutic use; D007223:Infant; D007431:Intraoperative Complications; D019654:Lens Implantation, Intraocular; D011446:Prospective Studies; D014822:Vitreous Body / Q000473:pathology*
D006820:Hyaluronic Acid